Join TechBio Companies Driving Patient Impact

Sponsored by Alix Ventures

Post a job // Join our newsletter
BIOS Community
BIOS Community
ReCode Therapeutics
ReCode Therapeutics


San Francisco, CA, USA · Menlo Park, CA, USA · Dallas, TX, USA


51-200 employees

founded in


ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis. They have combined selected tRNAs with their unique and diverse proprietary delivery platforms to create and develop first-in-class suppressor tRNA-nanoparticle therapeutics for correcting nonsense mutations. ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF). The company’s proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery. ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing. The company was founded in 2015 and is based in Dallas, Texas.

Something looks off?
Open jobs at ReCode Therapeutics
This company does not have jobs relevant to this job board at this time.
To view all their jobs, visit their website.